Literature DB >> 18986274

Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia.

Brad Spellberg1, Thomas R Fleming, David N Gilbert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18986274      PMCID： PMC2692540          DOI： 10.1086/591389

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

1.  Trends in antimicrobial drug development: implications for the future.

Authors:  Brad Spellberg; John H Powers; Eric P Brass; Loren G Miller; John E Edwards
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

Review 2.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

3.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

4.  Current issues in non-inferiority trials.

Authors:  Thomas R Fleming
Journal:  Stat Med       Date:  2008-02-10       Impact factor: 2.373

5.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.

Authors:  Brad Spellberg; Robert Guidos; David Gilbert; John Bradley; Helen W Boucher; W Michael Scheld; John G Bartlett; John Edwards
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

Review 6.  Epidemiology and etiology of community-acquired pneumonia.

Authors:  Lionel A Mandell
Journal:  Infect Dis Clin North Am       Date:  2004-12       Impact factor: 5.982
  6 in total
  7 in total

1.  Combating antimicrobial resistance: policy recommendations to save lives.

Authors:  Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

Review 2.  Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Authors:  Brad Spellberg; George Talbot
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

3.  Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.

Authors:  Brad Spellberg; Roger J Lewis; Helen W Boucher; Eric P Brass
Journal:  Clin Investig (Lond)       Date:  2011-01-01

4.  Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.

Authors:  Marci L English; Christine E Fredericks; Nancy A Milanesio; Nestor Rohowsky; Ze-Qi Xu; Tuah R J Jenta; Michael T Flavin; David A Eiznhamer
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

5.  Are fluoroquinolones superior antibiotics for the treatment of community-acquired pneumonia?

Authors:  Timothy E Albertson; Brian M Morrissey; Andrew L Chan
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

6.  Endocan, a Risk Factor for Developing Acute Respiratory Distress Syndrome among Severe Pneumonia Patients.

Authors:  Jun Ying; Danfei Zhou; Tongjie Gu; Jianda Huang
Journal:  Can Respir J       Date:  2019-04-01       Impact factor: 2.409

7.  A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin.

Authors:  Jeff Kingsley; Purvi Mehra; Laura E Lawrence; Eugenia Henry; Erin Duffy; Sue K Cammarata; John Pullman
Journal:  J Antimicrob Chemother       Date:  2015-12-17       Impact factor: 5.790
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.